Press releases

Transcatheter aortic valve replacement technology for patients with severe aortic stenosis designed to minimize paravalvular leakage, offer controlled delivery and repositionability post deployment.

The inaccessibility of these products will severely limit treatment options for the 50% of women in the U.S. who will suffer from POP during their lives.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2019.

New data showcases safety & efficacy of recently acquired RF balloon-based, single-shot ablation technology when treating patients with AFib.

Company begins limited market release in Europe for next generation WATCHMAN device, intended to reduce the risk of stroke in people with non-valvular AFib.

Key data to be featured at European Heart Rhythm Association (EHRA) Congress include outcomes from the LUMINIZE RF balloon catheter for the treatment of AFib.

Solutions for nutrition support and early detection of respiratory issues win and place at Connected Patient Challenge competition focused on chronic conditions.

Boston Scientific will participate in the upcoming healthcare conference in February 2019. A live webcast and replay will be available.

Boston Scientific Corporation (NYSE: BSX) announced its completed public offering of senior notes.

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.

Boston Scientific will participate in the SVB Leerink healthcare conference in February 2019. A live webcast and replay will be available.

Patient safety is always our highest priority at Boston Scientific.

"Meaningful innovation and focused execution helped us deliver strong financial results in 2018," said CEO Mike Mahoney.

Rezūm patients experienced significant and sustained improvement in benign prostatic hyperplasia (BPH) symptoms and quality of life.

Advanced systems offer customizable therapy to treat Parkinson's symptoms.

Boston Scientific venous stent met VIRTUS trial primary effectiveness and safety endpoints in re-establishing blood flow.

All patent litigation between the companies to be dismissed.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 2018 and the full 2018 year.

Boston Scientific will webcast its conference call discussing financial results and business highlights for Q4 ended December 31, 2018. Learn how to tune in.

Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system

A live webcast and replay will be available. Learn how to tune in.

Delaware court rules Edwards Lifesciences Infringes Boston Scientific patent

Boston Scientific will participate in a healthcare investor conference in December 2018. A live webcast and replay will be available.

Boston Scientific will participate in Citi’s healthcare investor conference in December 2018. A live webcast and replay will be available.

In helping care for people living with complex, debilitating and often life-threatening conditions, patient safety is Boston Scientific’s highest priority.